Trial Profile

A post approval trial of NBTXR3 in soft tissue sarcoma

Status: Planning

Phase of Trial: Phase IV

Latest Information Update: 13 Jan 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Hafnium oxide (Primary)
Indications Soft tissue sarcoma
Focus Adverse reactions

Most Recent Events

08 Jan 2021 According to a Nanobiotix media release, the company expects to launch this study in EU by 2H 2021.
26 Oct 2020 According to a Nanobiotix media release, the company plans to launch this study in 2021.
24 Apr 2020 Planned initiation date changed to 1 Apr 2021.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com